129 related articles for article (PubMed ID: 32624941)
1. Combined optimization of N-terminal site-specific PEGylation of recombinant hirudin using response surface methodology and kinetic analysis.
Wang X; Wang S; Pan D; Qin K; Yuan H; Zhang F; Sun Y; Xiu Z
Eng Life Sci; 2018 Aug; 18(8):611-621. PubMed ID: 32624941
[TBL] [Abstract][Full Text] [Related]
2. PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics.
Na DH; Lee KC; DeLuca PP
Pharm Res; 2005 May; 22(5):743-9. PubMed ID: 15906169
[TBL] [Abstract][Full Text] [Related]
3. Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).
Pan LQ; Wang HB; Lai J; Xu YC; Zhang C; Chen SQ
Biomaterials; 2013 Dec; 34(36):9115-23. PubMed ID: 23981355
[TBL] [Abstract][Full Text] [Related]
4. A new site-specific monoPEGylated β-lactoglobulin at the N-terminal: Effect of different molecular weights of mPEG on its conformation and antigenicity.
Luo S; Ji L; Zhou L; Chen T; Zhong J; Liu W; Liu C
Food Chem; 2021 May; 343():128402. PubMed ID: 33406572
[TBL] [Abstract][Full Text] [Related]
5. [Interferon alpha-2b modified with polyethylene glycol].
Wu Y; Zhai Y; Lei J; Ma G; Su Z
Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1658-63. PubMed ID: 19160853
[TBL] [Abstract][Full Text] [Related]
6. Novel Bioconjugation Strategy Using Elevated Hydrostatic Pressure: A Case Study for the Site-Specific Attachment of Polyethylene Glycol (PEGylation) of Recombinant Human Ciliary Neurotrophic Factor.
Wang Q; Zhang C; Guo F; Li Z; Liu Y; Su Z
Bioconjug Chem; 2017 Nov; 28(11):2841-2848. PubMed ID: 29053917
[TBL] [Abstract][Full Text] [Related]
7. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight.
Zhai Y; Zhao Y; Lei J; Su Z; Ma G
J Biotechnol; 2009 Jul; 142(3-4):259-66. PubMed ID: 19497340
[TBL] [Abstract][Full Text] [Related]
8. Site-specific PEGylation of lidamycin and its antitumor activity.
Li L; Shang B; Hu L; Shao R; Zhen Y
Acta Pharm Sin B; 2015 May; 5(3):264-9. PubMed ID: 26579455
[TBL] [Abstract][Full Text] [Related]
9. Point mutations modifying the thrombin inhibition kinetics and antithrombotic activity in vivo of recombinant hirudin.
Degryse E; Acker M; Defreyn G; Bernat A; Maffrand JP; Roitsch C; Courtney M
Protein Eng; 1989 Mar; 2(6):459-65. PubMed ID: 2710782
[TBL] [Abstract][Full Text] [Related]
10. Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity.
Lee BK; Kwon JS; Kim HJ; Yamamoto S; Lee EK
Bioconjug Chem; 2007; 18(6):1728-34. PubMed ID: 17941681
[TBL] [Abstract][Full Text] [Related]
11. Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin.
Nie Y; Zhang X; Wang X; Chen J
Bioconjug Chem; 2006; 17(4):995-9. PubMed ID: 16848407
[TBL] [Abstract][Full Text] [Related]
12. Optimization of the medium for Lactobacillus acidophilus by Plackett-Burman and steepest ascent experiment.
Chen H; Niu J; Qin T; Ma Q; Wang L; Shu G
Acta Sci Pol Technol Aliment; 2015; 14(3):227-232. PubMed ID: 28068030
[TBL] [Abstract][Full Text] [Related]
13. Evaluating prodrug characteristics of a novel anticoagulant fusion protein neorudin, a prodrug targeting release of hirudin variant 2-Lys47 at the thrombosis site, by means of in vitro pharmacokinetics.
Dong X; Gu R; Zhu X; Gan H; Liu J; Jin J; Meng Z; Dou G
Eur J Pharm Sci; 2018 Aug; 121():166-177. PubMed ID: 29802897
[TBL] [Abstract][Full Text] [Related]
14. Design, development and evaluation of PEGylated rhGH with preserving its bioactivity at highest level after modification.
Karbasian M; Kouchakzadeh H; Anamaghi PN; Sefidbakht Y
Int J Pharm; 2019 Feb; 557():9-17. PubMed ID: 30576790
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of PEGyated Concanavalin A for affinity chromatography with improved stability.
Wen Z; Niemeyer B
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(20):1732-40. PubMed ID: 21571597
[TBL] [Abstract][Full Text] [Related]
16. Improving Properties of Recombinant SsoPox by Site-Specific Pegylation.
Parikh H; Bajaj P; Tripathy RK; Pande AH
Protein Pept Lett; 2015; 22(12):1098-103. PubMed ID: 26428299
[TBL] [Abstract][Full Text] [Related]
17. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
[TBL] [Abstract][Full Text] [Related]
18. Solid-phase N-terminus PEGylation of recombinant human fibroblast growth factor 2 on heparin-sepharose column.
Huang Z; Ye C; Liu Z; Wang X; Chen H; Liu Y; Tang L; Zhao H; Wang J; Feng W; Li X
Bioconjug Chem; 2012 Apr; 23(4):740-50. PubMed ID: 22433083
[TBL] [Abstract][Full Text] [Related]
19. Optimization of PEGylation reaction time and molar ratio of rhG-CSF toward increasing bioactive potency of monoPEGylated protein.
Behi J; Hassiki R; Said NB; Bouhaouala-Zahar B; Benkhoud ML
Int J Biol Macromol; 2018 Apr; 109():888-895. PubMed ID: 29154875
[TBL] [Abstract][Full Text] [Related]
20. Solid-phase polyethylene glycol conjugation using hydrophobic interaction chromatography.
Niu J; Zhu Y; Xie Y; Song L; Shi L; Lan J; Liu B; Li X; Huang Z
J Chromatogr A; 2014 Jan; 1327():66-72. PubMed ID: 24411087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
